An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 24, 2018

Primary Completion Date

April 25, 2021

Study Completion Date

August 20, 2025

Conditions
Lung CancerNon-Small Cell Lung Cancer
Interventions
DRUG

BMS-986205

Administered orally daily, 100 mg

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Chemotherapy

Platinum-based doublet chemotherapy

Trial Locations (83)

1090

Local Institution, Vienna

2010

Local Institution, Darlinghurst

2340

Local Institution, North Tamworth

3004

Local Institution, Melbourne

4031

Local Institution, Basel

4102

Local Institution, Brisbane

4600

Local Institution, Wels

6150

Local Institution, Murdoch

11217

Local Institution, Taipei

11527

Local Institution, Athens

14165

Local Institution, Berlin

15006

Local Institution, A Coruña

17325

Local Institution, Gettysburg

18547

Local Institution, Athens

20900

Local Institution, Monza (MB)

21075

Local Institution, Hamburg

22927

Local Institution, Großhansdorf

25030

Local Institution, Besançon

26121

Local Institution, Oldenburg

28041

Local Institution, Madrid

28222

Local Institution, Majadahonda - Madrid

29010

Local Institution, Málaga

29607

Local Institution, Greenville

30033

Local Institution, Decatur

30060

Local Institution, Marietta

32256

Local Institution, Jacksonville

32308

Local Institution, Tallahassee

33098

Local Institution, Paderborn

33401

Local Institution, West Palm Beach

33604

Local Institution, Pessac

33705

Local Institution, St. Petersburg

33916

Local Institution, Fort Myers

34098

Local Institution, Istanbul

34890

Local Institution, ?stanbul

35033

Local Institution, Rennes

37075

Local Institution, Göttingen

37087

Local Institution, Lebanon

38700

Local Institution, La Tronche

40202

Local Institution, Louisville

41100

Local Institution, Modena

42100

Local Institution, Reggio Emilia

44106

Local Institution, Cleveland

44805

Local Institution, Saint-Herblain

46026

Local Institution, Valencia

48121

Local Institution, Ravenna

63044

Local Institution, Bridgeton

65199

Local Institution, Wiesbaden

67214

Local Institution, Wichita

68510

Local Institution, Lincoln

69126

Local Institution, Heidelberg

74374

Local Institution, Pringy

75248

Local Institution, Paris

76104

Local Institution, Fort Worth

80131

Local Institution, Napoli

82131

Local Institution, Gauting

83000

Local Institution, Toulon

92123

Local Institution, San Diego

97070

Local Institution, Mérida

5898511

Local Institution, Osaka-sayama-shi

9601295

Local Institution, Fukushima

02114

Local Institution, Boston

79430-0002

Local Institution, Lubbock

35160-158

Local Institution, Ipatinga

86015-520

Local Institution, Jd. Petropolis-Londrina

90050-170

Local Institution, Centro-porto Alegre

98700-000

Local Institution, Ijuí

90610-000

Local Institution, Porto Alegre

14780-070

Local Institution, Barretos

05652-900

Local Institution, Morumbi

22793-080

Local Institution, Rio de Janeiro

G1R 2J6

Local Institution, Québec

128 08

Local Institution, Prague

07548

Local Institution, Gera

54 622

Local Institution, Thessaloniki

06132

Local Institution, Perugia

0208505

Local Institution, Morioka

362-0806

Local Institution, Kitaadachi-gun

03080

Local Institution, Seoul

135-710

Local Institution, Seoul

08035

Local Institution, Barcelona

Unknown

Local Institution, Taipei

01250

Local Institution, Adana

07070

Local Institution, Antalya

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY